ADME毒性試験市場規模、シェア、成長分析：手法別、技術別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

ADME毒性試験市場規模は2023年に104億米ドルと評価され、2024年の116億5,000万米ドルから2032年には288億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは12.0％で成長する見通しです。

ADME毒性試験市場は、医薬品開発と安全性評価に不可欠な物質の薬物動態と毒物動態の評価において重要な役割を果たしています。製薬企業が厳しい規制要件を満たし、患者の安全性を確保するためにこれらの検査に傾注しているため、より安全で効果的な医薬品への需要が市場の成長を牽引しています。堅調な市場ダイナミクスにもかかわらず、ヒトの生理学的複雑性、コスト制約、進化する規制ガイドラインなどの課題は依然として残っています。しかし、in vitroおよびin silico検査法の進歩や個別化医療の台頭には有望な機会があります。米国のADME毒性試験市場は、技術革新と規制遵守を原動力として、次の予測期間にわたって持続的な成長を遂げると予測されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

ADME毒性試験市場規模：手法別& CAGR（2025-2032）

• 市場概要
• 細胞アッセイ
• 生化学分析
• シリカ
• 生体外

ADME毒性試験市場規模：技術別& CAGR（2025-2032）

• 市場概要
• 細胞培養
• 高スループット
• 分子イメージング
• オミックス技術

ADME毒性試験市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 全身毒性
• 腎毒性
• 肝毒性
• 神経毒性
• その他

ADME毒性試験市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院と診療所
• 診断センター
• 病理学研究室
• その他

ADME毒性試験市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Charles River Laboratories（USA）
• Eurofins Scientific（Luxembourg）
• WuXi AppTec（China）
• SGS SA（Switzerland）
• PPD（USA）
• Covance Inc.（USA）
• ICON plc（Ireland）
• LabCorp（USA）
• Syneos Health（USA）
• IQVIA（USA）
• Boehringer Ingelheim（Germany）
• Merck & Co.（USA）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• GlaxoSmithKline plc（UK）
• Sanofi（France）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Eli Lilly and Company（USA）

結論と提言

ADME Toxicology Testing Market size was valued at USD 10.4 billion in 2023 and is poised to grow from USD 11.65 billion in 2024 to USD 28.84 billion by 2032, growing at a CAGR of 12.0% during the forecast period (2025-2032).

The ADME toxicology testing market plays a crucial role in evaluating the pharmacokinetics and toxicokinetics of substances, critical for drug development and safety assessments. Demand for safer and more effective drugs drives market growth, as pharmaceutical companies lean on these tests to meet stringent regulatory requirements and ensure patient safety. Despite the robust market dynamics, challenges such as human physiological complexities, cost constraints, and evolving regulatory guidelines persist. However, there are promising opportunities in advancements in in vitro and in silico testing methods, as well as the rise of personalized medicine. The US ADME Toxicology Testing Market is projected to experience sustainable growth over the next forecast period, indicating a solid trajectory driven by innovation and regulatory compliance.

Top-down and bottom-up approaches were used to estimate and validate the size of the Adme Toxicology Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Adme Toxicology Testing Market Segments Analysis

Global ADME Toxicology Testing Market is segmented by Method, Technology, Application, End Users and region. Based on Method, the market is segmented into Cellular Assay, Biochemical Assay, In Silica and Ex-vivo. Based on Technology, the market is segmented into Cell Culture, High Throughput, Molecular Imaging and OMICS Technology. Based on Application, the market is segmented into Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity and Others. Based on End Users, the market is segmented into Hospitals and clinics, Diagnostic centers, Pathological Labs and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Adme Toxicology Testing Market

In 2022, the pharmaceutical sector saw a significant increase in drug development activities, spurred by the demand for novel therapeutics targeting various health conditions. This intensification in drug discovery and development significantly propelled the ADME toxicology testing market. Pharmaceutical companies and research institutions relied heavily on toxicology assessments to evaluate the safety and effectiveness of their drug candidates, ensuring rigorous safety protocols before moving forward with clinical trials and eventual market entry. Consequently, the heightened emphasis on innovative drug solutions has fostered substantial growth in the ADME toxicology testing market, underscoring its critical role in the drug development process.

Restraints in the Adme Toxicology Testing Market

The ADME Toxicology Testing market faces notable restraints primarily due to the substantial costs involved in various experimental processes, specialized equipment, and the need for skilled personnel. In 2022, these financial burdens significantly impacted the market's growth potential, especially for small to medium-sized pharmaceutical companies operating with constrained budgets. The high expenses associated with ADME toxicology testing can deter investment and limit opportunities for innovation among these smaller firms, ultimately slowing the overall advancement and expansion of the market. Thus, the financial implications remain a critical barrier to growth within this sector, necessitating strategic solutions to mitigate these challenges.

Market Trends of the Adme Toxicology Testing Market

The Adme Toxicology Testing market is experiencing a significant shift towards in vitro and in silico testing advancements, which gained substantial traction in 2022. These innovative methodologies provide cost-effective, efficient, and ethical alternatives to traditional animal testing, propelling the industry toward more humane practices. The growing emphasis on regulatory compliance and risk assessment has catalyzed the development of sophisticated in vitro assays and predictive modeling techniques, enhancing the accuracy and reliability of toxicology evaluations. As stakeholders increasingly prioritize sustainability and ethical considerations, the market is poised for sustained growth, driven by the continued integration of cutting-edge technologies in toxicological assessments.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global ADME Toxicology Testing Market Size by Method & CAGR (2025-2032)

• Market Overview
• Cellular Assay
• Biochemical Assay
• In Silica
• Ex-vivo

Global ADME Toxicology Testing Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Cell Culture
• High Throughput
• Molecular Imaging
• OMICS Technology

Global ADME Toxicology Testing Market Size by Application & CAGR (2025-2032)

• Market Overview
• Systemic Toxicity
• Renal Toxicity
• Hepatotoxicity
• Neurotoxicity
• Others

Global ADME Toxicology Testing Market Size by End Users & CAGR (2025-2032)

• Market Overview
• Hospitals and clinics
• Diagnostic centers
• Pathological Labs
• Others

Global ADME Toxicology Testing Market Size & CAGR (2025-2032)

• North America (Method, Technology, Application, End Users)
  • US
  • Canada
• Europe (Method, Technology, Application, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Method, Technology, Application, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Method, Technology, Application, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Method, Technology, Application, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covance Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LabCorp (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations